2. NF-κB Metabolic Enzyme/Protease Immunology/Inflammation Anti-infection Apoptosis
  3. Keap1-Nrf2 NF-κB Reactive Oxygen Species (ROS) SARS-CoV Apoptosis
  4. Danshensu

Danshensu  (Synonyms: Dan shen suan A; Salvianic acid A)

Cat. No.: HY-N1913 Pureté: 99.90%
COA
SDS
Instruction de manipulation Technical Support

Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No. : 76822-21-4

Size Prix Stock Quantité
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water
ready for reconstitution
 En stock
Solution
10 mM * 1 mL in Water En stock
Solid
5 mg En stock
10 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtenir un devis  
500 mg   Obtenir un devis  

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Avis client

Based on 8 publication(s) in Google Scholar

Other Forms of Danshensu:

Danshensu Related Antibodies

Top Publications Citing Use of Products

    Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378.  [Abstract]

    Danshensu (DSS；40, 60 mg/kg; IP; daily for 7 days) significantly increased the flap survival rate in the C57BL/6J mouse.

    Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378.  [Abstract]

    Danshensu (DSS；40, 60 mg/kg; IP; daily for 7 days) increased the protein expression of Cadherin5, MMP9, and VEGFA in the C57BL/6J mouse. Representative western blot images of Cadherin5, MMP9, and VEGFA in mouse skin tissue lysates, with density quantification and statistical analysis of protein levels in each group.

    Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378.  [Abstract]

    Danshensu (DSS; 40, 60 mg/kg; IP; daily for 7 days) showed the number of blood vessels significantly decreased after ischemic injury of the skin flap. This result was reversed with the use of DSS.

    Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378.  [Abstract]

    Danshensu (DSS; 40, 60 mg/kg; IP; daily for 7 days) increased average vessel density in mouse.

    Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378.  [Abstract]

    Danshensu (DSS; 40, 60 mg/kg; IP; daily for 7 days) showed that the proportion of GSDMD-N and Caspase-1 positive cells was considerably higher following ischemic injury of the skin flap and notably reduced after DSS treatment. Immunofluorescence staining of Caspase-1 (red) on skin tissue sections from each group, with DAPI staining for cell nuclei (blue).

    Danshensu purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb:137:156378.  [Abstract]

    Danshensu (DSS; 40, 60 mg/kg; IP; daily for 7 days) decreased the protein expression of GSDMD-N and Caspase-1 in C57BL/6 J mice.

    Voir tous les produits spécifiques à Isoform NF-κB:

    Voir toutes les isoformes
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    • Activité biologique

    • Pureté et documentation

    • Références

    • Avis client

    Description

    Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research[1][2][3].

    In Vitro

    Danshensu (Dan shen suan A) potently inhibits the entry of SARS-CoV-2 S protein-pseudo-typed virus (SARS-CoV-2 S) into ACE2-overexpressed HEK-293T cells (IC50=0.31 μM) and Vero-E6 cell (IC50=4.97 μM)[1].
    Danshensu (0-100 μM; for 24 h) at higher concentrations (50 and 100 μM) causes significant reduction in migration and invasion of both FaDu and Ca9-22 cells[2].
    Danshensu (0-100 μM; for 24 h)dose-dependently reduced the phosphorylation of ERK and p38 phosphorylation in FaDu cell[2].
    Danshensu (0-100 μM; for 24, 48, 72 h) does not have any cytotoxic effect on human oral cancer cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Danshensu Related Antibodies

    Cell Migration Assay [2]

    Cell Line: FaDu and Ca9-22 cells
    Concentration: 25, 50, and 100 μM
    Incubation Time: 24 h
    Result: At higher concentrations (50 and 100 μM) caused significant reduction in migration and invasion of both FaDu and Ca9-22 cells.

    Western Blot Analysis[2]

    Cell Line: FaDu and Ca9-22 cells
    Concentration: 25, 50, and 100 μM
    Incubation Time: 24 h
    Result: Phosphorylation of ERK reduced dose-dependently after 24 h in FaDu cell.
    Caused significant reduction in p38 phosphorylation.
    In Vivo

    Danshensu (Dan shen suan A; 25, 50, 100 mg/kg; oral administration daily for 7 continuous days or i.v. once) before SARS-CoV-2 S infection dose-dependently alleviates the pathological alterations in mice infected with SARS-CoV-2 S[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Adult BALB/c mice (male, 6-8 weeks, 20±2 g)[1]
    Dosage: 25, 50, 100 mg/kg
    Administration: Oral administration (daily for 7 continuous days) or i.v. (once)
    Result: Could prevent SARS-CoV-2 S protein-induced acute lung inflammation.
    Ameliorated inflammatory cytokines in serum and lung tissue.
    Masse moléculaire

    198.17

    Formule

    C9H10O5
    CAS No.
    Appearance

    Solid

    Color

    White to gray

    SMILES

    OC1=C(C=CC(C[C@H](C(O)=O)O)=C1)O
    Structure Classification
    Initial Source
    Livraison

    Room temperature in continental US; may vary elsewhere.
    Stockage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvant et solubilité
    In Vitro: 

    H2O : 5 mg/mL (25.23 mM; Need ultrasonic)

    DMSO : < 1 mg/mL (insoluble or slightly soluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.0462 mL 25.2309 mL 50.4617 mL
    5 mM 1.0092 mL 5.0462 mL 10.0923 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Calculateur de molarité

    • Calculateur de dilution

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 10 mg/mL (50.46 mM); Clear solution; Need ultrasonic and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Pureté et documentation
    Références

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O 1 mM 5.0462 mL 25.2309 mL 50.4617 mL 126.1543 mL
    5 mM 1.0092 mL 5.0462 mL 10.0923 mL 25.2309 mL
    10 mM 0.5046 mL 2.5231 mL 5.0462 mL 12.6154 mL
    15 mM 0.3364 mL 1.6821 mL 3.3641 mL 8.4103 mL
    20 mM 0.2523 mL 1.2615 mL 2.5231 mL 6.3077 mL
    25 mM 0.2018 mL 1.0092 mL 2.0185 mL 5.0462 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Danshensu Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Danshensu76822-21-4Dan shen suan A Salvianic acid AKeap1-Nrf2NF-κBReactive Oxygen Species (ROS)SARS-CoVApoptosisNuclear factor-κBNuclear factor-kappaBSARS coronavirusOrallyHO-1antioxidant defense mechanismanti-oxidationanti-apoptosislung inflammatoryCOVID-19cardiovascularcerebrovascularInhibitorinhibitorinhibit

    Vos produits récemment consultés:

    Demande en ligne

    Your information is safe with us. * Required Fields.

    Nom du produit

    		  

    Requested Quantity *

    Nom du demandeur *

    		 

    Civilité

    Adresse e-mail *

    		 

    Numéro de téléphone *

    Department

    		 

    Nom de l'organisation *

    City

    État

    Country or Region *

    		      

    Remarques

    Bulk Inquiry

    Inquiry Information

    Nom du produit:
    Danshensu
    Cat. No.:
    HY-N1913
    Quantité:
    MCE Japan Authorized Agent:

    Avis client

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nom du produit

    		  

    Lot #

    Nom du demandeur *

    		 

    Adresse e-mail *

    Numéro de téléphone

    		 

    Department *

    Nom de l'organisation *

    		 

    Country or Region *

    Remarques

    SAFETY DATA SHEET (SDS)

    English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.